IN8bio(US:INAB)2025-05-07 20:01Financial Performance - IN8bio reported a net loss of $5.6 million, or $0.07 per share, for Q1 2025, compared to a net loss of $8.6 million, or $0.20 per share, in the same period last year[18]. - Net loss for Q1 2025 was $5,550 million, compared to a net loss of $8,562 million in Q1 2024, indicating an improvement of 35.9%[23]. - Net loss per share improved from $(0.20) in Q1 2024 to $(0.07) in Q1 2025[23]. - Total operating expenses for Q1 2025 were $5,660 million, down 34.4% from $8,645 million in Q1 2024[23]. - Interest income increased from $83 million in Q1 2024 to $110 million in Q1 2025, a growth of 32.5%[23]. Research and Development - Research and Development (R&D) expenses decreased to $3.0 million in Q1 2025 from $4.9 million in the prior year, primarily due to reduced clinical trial activities[14]. - Research and development expenses decreased from $4,903 million in Q1 2024 to $2,972 million in Q1 2025, a reduction of 39.4%[23]. - The INB-600 TCE platform was presented at the AACR 2025 Annual Meeting, showcasing its potential applications in oncology and autoimmune diseases[4]. - The company is advancing its differentiated pipeline, including INB-600, which targets both Vδ1+ and Vδ2+ T cell subsets to enhance therapeutic efficacy[8]. Clinical Outcomes - INB-100 demonstrated a 100% relapse-free rate in treated Acute Myeloid Leukemia (AML) patients with a median follow-up of 20.1 months as of January 17, 2025[4]. - The 1-year progression-free survival (PFS) rate for all leukemia patients treated with INB-100 was reported at 90.9%, with a 1-year overall survival (OS) rate of 100%[8]. - Upcoming milestones include an oral presentation of INB-200 at the ASCO 2025 Annual Meeting on May 30, 2025[8]. Financial Position - The company had cash of $11.9 million as of March 31, 2025, compared to $13.0 million in the same period last year[18]. - Total assets decreased from $20,944 million as of December 31, 2024, to $19,869 million as of March 31, 2025, representing a decline of approximately 5.1%[21]. - Total liabilities decreased from $6,466 million to $5,992 million, a reduction of about 7.3%[21]. - Total stockholders' equity decreased from $14,478 million to $13,877 million, reflecting a decline of approximately 4.2%[21]. - The company reported a total current asset increase from $12,578 million to $12,725 million, a rise of approximately 1.2%[21]. Capital Raising - IN8bio raised approximately $4.1 million from the sale of common stock and the exercise of warrants in Q1 2025[4]. - Weighted-average number of shares used in computing net loss per share increased from 43,287,325 in Q1 2024 to 83,482,125 in Q1 2025[23]. Cost Management - General and Administrative (G&A) expenses were $2.7 million for Q1 2025, down from $3.7 million in the comparable prior year period, reflecting cost savings in personnel and professional services[15].